Total Payments
$19,798
2024 Payments
$3,258
Companies
42
Transactions
788
Medicare Patients
2,611
Medicare Billing
$3.4M
Payment Breakdown by Category
Food & Beverage$14,737 (74.4%)
Consulting$3,800 (19.2%)
Travel$1,024 (5.2%)
Education$236.81 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,737 | 779 | 74.4% |
| Consulting Fee | $3,800 | 1 | 19.2% |
| Travel and Lodging | $1,024 | 1 | 5.2% |
| Education | $236.81 | 7 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,216 | 63 | $0 (2024) |
| UCB, Inc. | $2,044 | 135 | $0 (2024) |
| ABBVIE INC. | $1,976 | 91 | $0 (2024) |
| Janssen Biotech, Inc. | $1,853 | 100 | $0 (2024) |
| Amgen Inc. | $1,728 | 77 | $0 (2024) |
| Lilly USA, LLC | $604.33 | 31 | $0 (2024) |
| PFIZER INC. | $577.11 | 36 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $527.30 | 29 | $0 (2024) |
| Horizon Therapeutics plc | $498.24 | 32 | $0 (2023) |
| GlaxoSmithKline, LLC. | $490.40 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,258 | 140 | Janssen Biotech, Inc. ($661.86) |
| 2023 | $7,032 | 103 | Novartis Pharmaceuticals Corporation ($5,273) |
| 2022 | $1,428 | 70 | Amgen Inc. ($267.36) |
| 2021 | $983.86 | 48 | AbbVie Inc. ($164.62) |
| 2020 | $781.59 | 38 | UCB, Inc. ($143.51) |
| 2019 | $3,465 | 211 | Amgen Inc. ($487.49) |
| 2018 | $1,915 | 114 | UCB, Inc. ($432.76) |
| 2017 | $935.21 | 64 | UCB, Inc. ($215.28) |
All Payment Transactions
788 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: Dermatology | ||||||
| 12/20/2024 | ANI Pharmaceuticals, Inc. | SOVUNA (Drug) | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: Treatment of uncomplicated malaria | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $54.99 | General |
| Category: Immunology | ||||||
| 12/16/2024 | TerSera Therapeutics LLC | Quzyttir (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Acute Care | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | ILARIS (Drug) | Food and Beverage | In-kind items and services | $29.52 | General |
| Category: Immunology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $28.60 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $61.57 | General |
| Category: Rare Disease | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $33.89 | General |
| Category: IMMUNOLOGY | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Immunology | ||||||
| 11/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $3.17 | General |
| Category: Immunology | ||||||
| 11/09/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: Immunology | ||||||
| 11/08/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Inflammation | ||||||
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Immunology | ||||||
| 11/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.12 | General |
| Category: Immunology | ||||||
| 11/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Immunology | ||||||
| 11/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $1.15 | General |
| Category: Immunology | ||||||
| 11/03/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $0.67 | General |
| Category: Immunology | ||||||
| 10/28/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $21.92 | General |
| Category: Immunology | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: Dermatology | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $32.35 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 809 | 101,010 | $1.4M | $589,500 |
| 2022 | 11 | 632 | 121,979 | $1.6M | $715,127 |
| 2021 | 13 | 610 | 146,888 | $1.9M | $1.0M |
| 2020 | 10 | 560 | 138,227 | $1.8M | $1.0M |
Total Patients
2,611
Total Services
508,104
Medicare Billing
$3.4M
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 28 | 94,000 | $1.0M | $365,779 | 35.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 78 | 5,460 | $153,098 | $99,176 | 64.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 399 | $75,012 | $40,165 | 53.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 28 | 470 | $63,051 | $32,489 | 51.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 155 | 184 | $24,727 | $13,142 | 53.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 16 | 100 | $24,356 | $12,339 | 50.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 84 | 84 | $23,746 | $11,925 | 50.2% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 25 | 100 | $16,092 | $9,733 | 60.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $4,464 | $2,036 | 45.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 92 | 112 | $5,062 | $1,400 | 27.6% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 11 | 14 | $1,462 | $825.86 | 56.5% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 33 | 63 | $630.00 | $489.66 | 77.7% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 31 | 116,000 | $1.3M | $521,008 | 40.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 49 | 4,560 | $127,862 | $77,396 | 60.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 32 | 581 | $77,941 | $43,450 | 55.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 219 | 370 | $69,572 | $39,211 | 56.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 98 | 116 | $15,455 | $8,616 | 55.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 62 | $15,101 | $8,407 | 55.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 53 | 53 | $14,876 | $7,415 | 49.8% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2022 | 27 | 82 | $13,195 | $6,238 | 47.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 23 | 23 | $4,606 | $1,863 | 40.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 59 | 93 | $4,140 | $1,230 | 29.7% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 27 | 39 | $390.00 | $293.70 | 75.3% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2021 | 35 | 141,600 | $1.6M | $827,920 | 53.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 37 | 3,660 | $102,626 | $59,959 | 58.4% |
About Dr. Mahsa Tehrani, M.D
Dr. Mahsa Tehrani, M.D is a Rheumatology healthcare provider based in Vienna, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2009. The National Provider Identifier (NPI) number assigned to this provider is 1710113378.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mahsa Tehrani, M.D has received a total of $19,798 in payments from pharmaceutical and medical device companies, with $3,258 received in 2024. These payments were reported across 788 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($14,737).
As a Medicare-enrolled provider, Tehrani has provided services to 2,611 Medicare beneficiaries, totaling 508,104 services with total Medicare billing of $3.4M. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Vienna, VA
- Active Since 06/09/2009
- Last Updated 03/03/2015
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1710113378
Products in Payments
- COSENTYX (Drug) $5,481
- Cimzia (Drug) $1,881
- RINVOQ (Biological) $1,107
- SIMPONI ARIA (Biological) $915.37
- TREMFYA (Drug) $861.86
- Enbrel (Biological) $827.20
- Otezla (Drug) $598.33
- TALTZ (Drug) $561.19
- ACTHAR (Biological) $554.13
- ORENCIA (Biological) $512.70
- XELJANZ (Drug) $507.36
- BENLYSTA (Biological) $490.40
- COSENTYX (Biological) $449.62
- Rituxan (Biological) $411.21
- KRYSTEXXA (Biological) $394.55
- Humira (Biological) $340.96
- ILARIS (Drug) $267.63
- EVENITY (Biological) $245.01
- LUPKYNIS (Drug) $202.30
- PENNSAID (Drug) $190.63
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.